Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 2Lymphoid 2Gastrointestinal 2Dermatologic 2Thoracic 1Head & Neck 1

Conditions

Melanoma 2Uveal Melanoma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Valproic Acid × Dermatologic × Clear all
NCT04729543 2023-12-04

MC2TCR

Erasmus Medical Center

Phase 1/2 Recruiting
20 enrolled
DermatologicHead & Neck

Uveal Melanoma, Head and Neck Neoplasms, Melanoma

NCT00358319 2013-11-25

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
42 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡